This Article Full Text Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Services Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Dwyer, R.M. Articles by Kerin, M.J. Search for Related Content PubMed PubMed Citation Articles by Dwyer, R.M. Articles by Kerin, M.J.

Monocyte Chemotactic Protein-1 Secreted by Primary Breast Tumors Stimulates Migration of Mesenchymal Stem Cells

Authors' Affiliations: ¹ Department of Surgery and ² Regenerative Medicine Institute and Department of Medicine, National University of Ireland, Galway, Ireland

Requests for reprints: Michael Kerin, Department of Surgery, Clinical Science Institute, National University of Ireland Galway, Ireland. E-mail: michael.kerin{at}nuigalway.ie or Roisin Dwyer, Department of Surgery, Clinical Science Institute, National University of Ireland Galway, Ireland. Phone: 91-544637; Fax: 11-353-091-494509; E-mail: roisin.dwyer{at}nuigalway.ie.

Purpose: Major barriers to effective adenovirus-based gene therapy include induction of an immune response and tumor-specific targeting of vectors. The use of mesenchymal stem cells (MSC) as systemic delivery vehicles for therapeutic genes has been proposed as a result of their combined ability to home in on the tumor site and evade the host immune response. This study is aimed at investigating factors mediating homing of human MSCs to breast cancer primary cultures and cell lines in vitro and in vivo.

Experimental Design: Fluorescently labeled MSCs were given to mice bearing breast cancer xenografts, and tumor tissue was harvested to detect MSC engraftment. MSC migration in response to primary breast tumors in vitro was quantified, and chemokines secreted by tumor cells were identified. The role of monocyte chemotactic protein-1 (MCP-1) in cell migration was investigated using antibodies and standards of the chemokine. Serum MCP-1 was measured in 125 breast cancer patients and 86 healthy controls.

Results: Engrafted MSCs were detected in metastatic breast tumors in mice after systemic administration. There was a significant increase in MSC migration in response to primary breast tumor cells in vitro (6-fold to 11-fold increase). Tumor explants secreted a variety of chemokines including GRO, MCP-1, and stromal cell–derived factor-1. An MCP-1 antibody caused a significant decrease (37-42%) in MSC migration to tumors. Serum MCP-1 levels were significantly higher in postmenopausal breast cancer patients than age-matched controls (P < 0.05).

Conclusions: These results highlight a role for tumor-secreted MCP-1 in stimulating MSC migration and support the potential of these cells as tumor-targeted delivery vehicles for therapeutic agents.

This article has been cited by other articles:

				G. Lazennec and C. Jorgensen Concise Review: Adult Multipotent Stromal Cells and Cancer: Risk or Benefit? Stem Cells, June 1, 2008; 26(6): 1387 - 1394. [Abstract] [Full Text] [PDF]

				A. J. Lowery, N. Miller, R. E. McNeill, and M. J. Kerin MicroRNAs as Prognostic Indicators and Therapeutic Targets: Potential Effect on Breast Cancer Management Clin. Cancer Res., January 15, 2008; 14(2): 360 - 365. [Abstract] [Full Text] [PDF]